Semaglutide vs Tirzepatide: Which Is Cheaper Per Pound Lost? (2026)

On a pure cost-per-pound basis, tirzepatide usually edges ahead. Its list price runs slightly lower (roughly $1,000-1,100/month versus $1,200-1,350 for semaglutide) yet it delivers more weight loss in trials — about 20-22% versus 15-17%. Divide the monthly price by the percentage shed and tirzepatide comes out cheaper per point of body weight lost. That said, what you actually pay depends on your insurance tier and savings card, so run your own out-of-pocket number before assuming one is the bargain.

Not necessarily, and sometimes less. Switching classes is routine when a prescriber signs off on it, often because someone has stalled on semaglutide. Because tirzepatide's list price is comparable or lower, the sticker shock is rarely the issue — the cost variable is whether your plan covers Mounjaro or Zepbound and at what copay tier. Ask your pharmacy to run both before you decide. Prescribers also restart you at a low dose, so your first months on tirzepatide may use cheaper lower-strength pens.

Tirzepatide hits two receptors — GLP-1 and GIP — while semaglutide hits only GLP-1. That second target adds insulin-sensitivity benefits and extra appetite signaling, which is why trial subjects lost more weight on it. From a value lens, you are paying a similar (or lower) monthly price for a stronger average result, which is what pushes the cost-per-pound math in tirzepatide's favor. More output for the same input is the whole argument.

The side-effect profiles are nearly identical — nausea, vomiting, diarrhea, and constipation top both lists, and both are worst while you titrate up. Tirzepatide showed marginally higher GI rates at the top dose, but nothing that meaningfully changes the financial picture. The hidden cost on either drug is the same: if side effects force you to pause or drop doses, you stretch out the timeline and pay for more months overall. Tolerability is personal, not class-driven.

Cash list prices are in the same ballpark. Tirzepatide (Mounjaro, Zepbound) sits around $1,000-1,100 per month, and semaglutide (Ozempic, Wegovy) around $1,200-1,350. But almost nobody pays sticker — manufacturer savings cards from Eli Lilly and Novo Nordisk, vial-based self-pay programs, and telehealth cash bundles all knock the real number down. Where your plan lands one drug versus the other on its formulary usually matters more to your wallet than the list-price gap.

Semaglutide is the veteran: Ozempic was approved in 2017 and Wegovy in 2021, so it carries more years of real-world safety data. Tirzepatide (Mounjaro 2022, Zepbound 2023) is newer but launched with a heavyweight trial program — the SURMOUNT and SURPASS series. If you value paying for a longer paper trail, semaglutide wins on history; if you value paying for peak measured results, tirzepatide wins on numbers. Both rest on extensive Phase 3 evidence.

Only on the semaglutide side, for now. As of early 2026 tirzepatide is injection-only, with oral orforglipron still in trials and not yet FDA-approved. Semaglutide already ships in pill form — Rybelsus for diabetes and oral Wegovy for weight loss, the latter launching around $149/month. So if pills are your preference and a lower entry price matters, semaglutide currently has both the option and, with oral Wegovy, an aggressive starting cost.